The 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (PH) were developed by the task force of the European Society of Cardiology (ESC) and European Respiratory Society (ERS), endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). The guidelines aim to provide a comprehensive, evidence-based approach to the diagnosis, classification, and management of PH, covering all five groups of PH. The guidelines emphasize a multidisciplinary approach, involving cardiologists, pneumologists, thoracic surgeons, and patients, and include detailed recommendations for diagnosis, risk stratification, treatment strategies, and follow-up. The guidelines also address specific subsets of PH, such as those associated with drugs, toxins, human immunodeficiency virus (HIV), portal hypertension, adult congenital heart disease, and schistosomiasis. The guidelines include a diagnostic algorithm, treatment algorithms for different PH groups, and recommendations for screening and early detection. They also provide guidance on the management of PH in pregnant women, patients with cardiopulmonary comorbidities, and those with advanced disease. The guidelines emphasize the importance of patient involvement, quality of care, and the use of evidence-based practices. The guidelines are intended for use by health professionals and are freely available in their respective journals. The guidelines are regularly updated to reflect new evidence and clinical practices. The guidelines also include tables of recommendations, tables of evidence grades, and tables of clinical classifications. The guidelines are accompanied by a detailed methodology section, including the use of systematic reviews, GRADE approach, and Evidence to Decision (EtD) framework. The guidelines are intended to assist health professionals in making informed decisions regarding the management of PH in individual patients. The guidelines are based on a thorough evaluation of available evidence and are intended to facilitate decision-making in daily clinical practice. The guidelines are not a substitute for the patient's relationship with their practitioner, and the final decisions regarding an individual patient must be made by the responsible health professional(s), based on what they consider to be the most appropriate in the circumstances. The guidelines are intended for use by health professionals and are freely available in their respective journals. The guidelines are regularly updated to reflect new evidence and clinical practices. The guidelines are accompanied by a detailed methodology section, including the use of systematic reviews, GRADE approach, and Evidence to Decision (EtD) framework. The guidelines are intended to assist health professionals in making informed decisions regarding the management of PH in individual patients. The guidelines are based on a thorough evaluation of available evidence and are intended to facilitate decision-making in daily clinical practice. The guidelines are not a substitute for the patient's relationship with their practitioner, and the final decisions regarding an individual patient must be made by the responsible health professional(s), based on what they consider to be the most appropriate in the circumstances.The 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (PH) were developed by the task force of the European Society of Cardiology (ESC) and European Respiratory Society (ERS), endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). The guidelines aim to provide a comprehensive, evidence-based approach to the diagnosis, classification, and management of PH, covering all five groups of PH. The guidelines emphasize a multidisciplinary approach, involving cardiologists, pneumologists, thoracic surgeons, and patients, and include detailed recommendations for diagnosis, risk stratification, treatment strategies, and follow-up. The guidelines also address specific subsets of PH, such as those associated with drugs, toxins, human immunodeficiency virus (HIV), portal hypertension, adult congenital heart disease, and schistosomiasis. The guidelines include a diagnostic algorithm, treatment algorithms for different PH groups, and recommendations for screening and early detection. They also provide guidance on the management of PH in pregnant women, patients with cardiopulmonary comorbidities, and those with advanced disease. The guidelines emphasize the importance of patient involvement, quality of care, and the use of evidence-based practices. The guidelines are intended for use by health professionals and are freely available in their respective journals. The guidelines are regularly updated to reflect new evidence and clinical practices. The guidelines also include tables of recommendations, tables of evidence grades, and tables of clinical classifications. The guidelines are accompanied by a detailed methodology section, including the use of systematic reviews, GRADE approach, and Evidence to Decision (EtD) framework. The guidelines are intended to assist health professionals in making informed decisions regarding the management of PH in individual patients. The guidelines are based on a thorough evaluation of available evidence and are intended to facilitate decision-making in daily clinical practice. The guidelines are not a substitute for the patient's relationship with their practitioner, and the final decisions regarding an individual patient must be made by the responsible health professional(s), based on what they consider to be the most appropriate in the circumstances. The guidelines are intended for use by health professionals and are freely available in their respective journals. The guidelines are regularly updated to reflect new evidence and clinical practices. The guidelines are accompanied by a detailed methodology section, including the use of systematic reviews, GRADE approach, and Evidence to Decision (EtD) framework. The guidelines are intended to assist health professionals in making informed decisions regarding the management of PH in individual patients. The guidelines are based on a thorough evaluation of available evidence and are intended to facilitate decision-making in daily clinical practice. The guidelines are not a substitute for the patient's relationship with their practitioner, and the final decisions regarding an individual patient must be made by the responsible health professional(s), based on what they consider to be the most appropriate in the circumstances.